Orthocell Ltd · ASX:OCC
Orthocell — Investor Presentation (September 2016)
21 slides from Orthocell's investor presentation, Sep 19, 2016
Slide 1: Investor Presentation - CelGro
| L C) th Gal ) | Investor Presentation - CelGro | September 2016 ft ASX: OCC Paul Anderson Managing Director
Slide 2: Disclaimer
Disclaimer For personal use only This presentation prepared by Orthocell Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall ther
Slide 3: Company Overview
Company Overview For personal use only Delivering breakthrough products in regenera6ve medicine: Regenera6ng Mobility Cell therapies: ‣ Ortho-ATI®. World’s first stem cell therapy to regenerate tendons ‣ Ortho-ACI®. Next genera6on car6lage repair ‣ Ac6vely engaging strategic partners in US and Japan
Slide 4: Corporate Overview
Corporate Overview For personal use only Experienced team to execute CEO Paul Anderson • Verigen Key Facts • Genzyme • Biomet ASX OCC CSO Prof. Ming Hao • Verigen Share Price AU$0.41 (@14th Sept 2016) Zheng • Genzyme • UWA Ordinary Shares on 91.2 million Execu6ve Dr Stewart • Cynata Issue Chairman W
Slide 5: Investment Opportunity
Investment Opportunity For personal use only SoK Tissue Repair - Global Need & Opportunity Age quake ‣ Musculoskeletal disorders are twice as common as cardio-vascular condi- 6ons ‣ Increased demand for safe, efficient, cost effec6ve treatments ‣ Global soK 6ssue repair market - US$7B in 2013 expected
Slide 6: A Paradigm Shift in Soft Tissue Reconstruction
CelGro ® For personal use only A Paradigm ShiK in SoK Tissue Reconstruc6on Celgro® is a pure collagen medical device manufactured by Orthocell to augment so5 6ssue and bone regenera6on. Ideal collagen scaffold quali6es: ‣ Compa(bility ‣ Guided (ssue repair/ op(mal (ssue integra(on remodeling CelGro®
Slide 7: Dental Application
CelGro ® For personal use only Dental Applica6on 7
Slide 8: Dental Opportunity
CelGro ® For personal use only Dental Opportunity ✙ 800 2 million million CelGro ® opportunity # annual dental membranes Value of addressable market •Guided tissue repair used in conjunction with in dental 1. •Optimal tissue remodeling bone graft substitutes 1. •Better bone quality 1. US, JP, EU & A
Slide 9: Tendon Application
CelGro ® For personal use only Tendon Applica6on 9
Slide 10: Tendon Opportunity
CelGro ® For personal use only Tendon Opportunity ✙ 1.6 CelGro ® 650,000 billion opportunity # annual rotator cuff Value of addressable market •Guided tissue repair procedures suitable for Celgro 1. in rotator cuff surgeries 1. •Optimal tissue remodeling •Reduced surgical failure rates 1. US, JP, EU
Slide 11: Pathway to Market
Pathway to Market For personal use only ® Near Term Regulatory Approvals - First CelGro EU Stage of Development Regulatory Targets 2. Product Current Applica1ons/Study Discovery Pre-clinical Clinical 0-6 months ThereaCer FDA (US) CE Mark (EU) Dental, guided bone, soft tissue regeneration ARTG (AUS)
Slide 12: CE Mark - CelGro First EU approval
CelGro - CE Mark ® For personal use only CelGro® First EU approval - guided bone regenera6on and soK 6ssue reconstruc6on What does it mean? ✓Authorised to market and distribute in the EU ✓EU approved manufacturing facility Benefits of a CE Mark: • Allows market entry in EU • Founda(on for regulatory
Slide 13: Platform: Value Increases With Every Additional Application
CelGro - PlaGorm ® For personal use only Value Increases With Every Addi6onal Applica6on + Orthopaedic / + Cartilage / Nerve + ACL CE Mark Dental Tendon 13
Slide 14: Month Milestones - Lead Applications
CelGro ® For personal use only 12 Month Milestones - Lead Applica6ons Regulatory Targets • EU approval for Dental applica(on - with regulatory applica(ons in other jurisdic(ons to follow (US, AUS, JP) • EU Tendon applica(on - with regulatory applica(ons in other jurisdic(ons to follow (US, AUS, JP)
Slide 15: For personal use only
For personal use only ➢ Superior products ➢ Significant de-risked opportunity ➢ Clear pathway to large markets ➢ Exper6se to partner and execute 15
Slide 16: Appendices
For personal use only Appendices 16
Slide 17: How CelGro Works
CelGro ® For personal use only How CelGro Works ® 17
Slide 18: Positioning CelGro
CelGro ® For personal use only Posi6oning CelGro ® +/- +/- +/- 18
Slide 19: Ortho-ATI: Autologous Tenocyte Implantation
Ortho-ATI ® For personal use only Orthocell’s Autologous Tenocyte Implanta6on Ortho-ATI® is a stem cell therapy to regenerate tendons and ligaments which: • uses each pa6ent’s own stem cells to regenerate tendon 6ssue • enables healing of tendons, reduces pain and increases strength • greatly improv
Slide 20: Ortho-ATI: Breakthrough Regenerative Medical Therapy
Ortho-ATI ® For personal use only Breakthrough Regenera6ve Medical Therapy Market leading world first tendon regenera(on treatment manufactured in Orthocell’s TGA licensed facility Over 300 pa6ents treated to date. Demonstrated pathway to market Non opera6ve procedure with high cost-benefit outcomes D
Slide 21: Ortho-ATI: Expansion Plans
Ortho-ATI ® For personal use only Expansion Plans Validated pathway to market • Referral pathway • Treatment pathway • Manufacturing op(misa(on • Tech transfer ready Bringing Ortho-ATI™ to the world’s largest markets: • IND being prepared for US Phase 2 tennis elbow study • partnering discussions on